Gilead reports that the next generation HIV medication, Descovy, has provided non-inferior to one of its mainstay therapies, Tuvada, in a late-stage trial that the big biotech says is the largest HIV prevention study conducted to date. The two year DISCOVER trial enrolled nearly 5,400 participants at risk for sexually acquired HIV infection. They received once-daily regimens of either Truvada or Descovy for HIV pre-exposure prophylaxis (PrEP). The results reveal that Descovy met the study’s primary endpoint. The sponsor reports that the investigational drug outperformed Truvada on secondary endpoints of bone and renal safety.